PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial.
PD-1/PD-L1 双特异性抗体 IBI318 与乐伐替尼联合治疗对免疫检查点抑制剂产生耐药性的晚期非小细胞肺癌：一项 II 期试验。
期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-025-67262-x
Zeng Liang, Ruan Zhaohui, Yan Huan, Qin Haoyue, Zeng Zhen, Zou Chun, Huang Zhe, Jiang Wenjuan, Dai Jiacheng, Xu Shidong, Song Lianxi, Chen Yangqian, Zhang Yuda, Zeng Fanxu, Wei Shiyou, Chen Shanmei, Liu Li, Xiong Yi, Wang Zhan, Deng Jun, Zhang Xing, Sun Yuanze, Yang Dan, Zhou Chunhua, Yang Haiyan, Li Yizhi, Deng Li, Xu Qinqin, Fang Chao, Chen Xue, Wang Jing, Li Ting, Zhang Gao, Zhou Hui, Yang Nong, Zhang Yongchang
肺癌
细胞生物学
PD-1
PD-L1
Checkpoint
